Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III study

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [21] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [22] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [23] Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): A phase III study.
    Langer, CJ
    Socinski, MA
    Ross, H
    O'Byrne, KJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1095S - 1095S
  • [24] A phase III study of induction therapy with gemcitabine plus carboplatin (GC) followed by either delayed vs. immediate second-line therapy with docetaxel (D) in advanced non-small cell lung cancer (NSCLC).
    Schiller, JH
    Fidias, P
    Dakhil, SR
    Lyss, AP
    Figueroa, JA
    Choksi, JK
    Loesch, DM
    Bloss, LP
    Ye, Z
    Obasaju, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 655S - 655S
  • [25] Cisplatin plus docetaxel as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)
    Doria, Simona
    Prochilo, Tiziana
    Cafferata, Mara Argenide
    Tiseo, Marcello
    Ardizzoni, Andrea
    Baldini, Editta
    ANNALS OF ONCOLOGY, 2007, 18 : 28 - 29
  • [26] A pilot study of weekly docetaxel and daily trofosfamide as metronomic second-line chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
    Gorn, M.
    Habermann, C.
    Thom, I.
    Schuch, G.
    Andritzky, B.
    Brandl, S.
    Burkholder, I.
    Hossfeld, D. K.
    Bokemeyer, C.
    Laack, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Biweekly paclitaxel as second-line treatment in advanced non-small-cell-lung-cancer (NSCLC).: A phase II study of the Galician Lung Cancer Group
    Vazquez-Estevez, S.
    Firvida, J. L.
    Grande, C.
    Baron, F.
    Lazaro, M.
    Salgado, M.
    Campos, B.
    Casal, J.
    Perez, E.
    Mel, J. R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 392 - 392
  • [28] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [29] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer
    Laack, E
    Dierlamm, T
    Knuffmann, C
    Popp, J
    Schmied, B
    Dürk, H
    Wacker-Backerhaus, G
    Zeller, W
    Verpoort, K
    Fiedler, W
    Hossfeld, DK
    LUNG CANCER, 2002, 36 (03) : 303 - 307
12345